Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

394 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment Algorithm for Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome Derived from a Canadian National Survey and Needs Assessment on Choices of Therapeutic Agents.
Tse Y, Armstrong D, Andrews CN, Bitton A, Bressler B, Marshall J, Liu LW. Tse Y, et al. Among authors: bitton a. Can J Gastroenterol Hepatol. 2017;2017:8612189. doi: 10.1155/2017/8612189. Epub 2017 Feb 8. Can J Gastroenterol Hepatol. 2017. PMID: 28271055 Free PMC article.
Canadian Association of Gastroenterology Clinical Practice Guidelines: the use of infliximab in Crohn's disease.
Panaccione R, Fedorak RN, Aumais G, Bernstein CN, Bitton A, Croitoru K, Enns R, Feagan B, Fishman M, Greenberg G, Griffiths A, Marshall JK, Rasul I, Sadowski D, Seidman E, Steinhart H, Sutherland L, Walli E, Wild G, Williams CN, Zachos M; Canadian Association of Gastroenterology. Panaccione R, et al. Among authors: bitton a. Can J Gastroenterol. 2004 Aug;18(8):503-8. doi: 10.1155/2004/670161. Can J Gastroenterol. 2004. PMID: 15372114 No abstract available.
Review and clinical perspectives for the use of infliximab in ulcerative colitis.
Panaccione R, Fedorak RN, Aumais G, Bernard EJ, Bernstein CN, Bitton A, Croitoru K, Dieleman LA, Enns R, Feagan BG, Franchimont D, Greenberg GR, Griffiths AM, Marshall JK, Pare P, Patel S, Penner R, Render C, Seidman E, Steinhart AH. Panaccione R, et al. Among authors: bitton a. Can J Gastroenterol. 2008 Mar;22(3):261-72. doi: 10.1155/2008/493405. Can J Gastroenterol. 2008. PMID: 18354755 Free PMC article. Review.
Inflammatory bowel disease: a Canadian burden of illness review.
Rocchi A, Benchimol EI, Bernstein CN, Bitton A, Feagan B, Panaccione R, Glasgow KW, Fernandes A, Ghosh S. Rocchi A, et al. Among authors: bitton a. Can J Gastroenterol. 2012 Nov;26(11):811-7. doi: 10.1155/2012/984575. Can J Gastroenterol. 2012. PMID: 23166905 Free PMC article. Review.
Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease.
Khanna R, Sattin BD, Afif W, Benchimol EI, Bernard EJ, Bitton A, Bressler B, Fedorak RN, Ghosh S, Greenberg GR, Marshall JK, Panaccione R, Seidman EG, Silverberg MS, Steinhart AH, Sy R, Van Assche G, Walters TD, Sandborn WJ, Feagan BG. Khanna R, et al. Among authors: bitton a. Aliment Pharmacol Ther. 2013 Sep;38(5):447-59. doi: 10.1111/apt.12407. Epub 2013 Jul 14. Aliment Pharmacol Ther. 2013. PMID: 23848220 Review.
Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics.
Devlin SM, Bressler B, Bernstein CN, Fedorak RN, Bitton A, Singh H, Feagan BG. Devlin SM, et al. Among authors: bitton a. Can J Gastroenterol. 2013 Oct;27(10):567-71. doi: 10.1155/2013/327120. Can J Gastroenterol. 2013. PMID: 24106727 Free PMC article. Review. No abstract available.
Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology.
Nguyen GC, Bernstein CN, Bitton A, Chan AK, Griffiths AM, Leontiadis GI, Geerts W, Bressler B, Butzner JD, Carrier M, Chande N, Marshall JK, Williams C, Kearon C. Nguyen GC, et al. Among authors: bitton a. Gastroenterology. 2014 Mar;146(3):835-848.e6. doi: 10.1053/j.gastro.2014.01.042. Epub 2014 Jan 22. Gastroenterology. 2014. PMID: 24462530 Review.
The probiotic VSL#3 has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn's disease.
Fedorak RN, Feagan BG, Hotte N, Leddin D, Dieleman LA, Petrunia DM, Enns R, Bitton A, Chiba N, Paré P, Rostom A, Marshall J, Depew W, Bernstein CN, Panaccione R, Aumais G, Steinhart AH, Cockeram A, Bailey RJ, Gionchetti P, Wong C, Madsen K. Fedorak RN, et al. Among authors: bitton a. Clin Gastroenterol Hepatol. 2015 May;13(5):928-35.e2. doi: 10.1016/j.cgh.2014.10.031. Epub 2014 Nov 6. Clin Gastroenterol Hepatol. 2015. PMID: 25460016 Clinical Trial.
Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus.
Bressler B, Marshall JK, Bernstein CN, Bitton A, Jones J, Leontiadis GI, Panaccione R, Steinhart AH, Tse F, Feagan B; Toronto Ulcerative Colitis Consensus Group. Bressler B, et al. Among authors: bitton a. Gastroenterology. 2015 May;148(5):1035-1058.e3. doi: 10.1053/j.gastro.2015.03.001. Epub 2015 Mar 4. Gastroenterology. 2015. PMID: 25747596 Review.
394 results